Antimicrobial resistance of Moraxella catarrhalis isolates in Taiwan  by Hsu, Shih-Fen et al.
Journal of Microbiology, Immunology and Infection (2012) 45, 134e140Available online at www.sciencedirect.com
journal homepage: www.e- jmii .comORIGINAL ARTICLE
Antimicrobial resistance of Moraxella catarrhalis
isolates in TaiwanShih-Fen Hsu a, Yi-Tsung Lin a, Te-Li Chen a,b, L.K. Siu c, Po-Ren Hsueh d,
Shih-Tse Huang a, Chang-Phone Fung a,b,*aDivision of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
bNational Yang-Ming University, Taipei, Taiwan
cDivision of Clinical Research, National Health Research Institutes, Zhunan, Taiwan
dDivision of Laboratory Medicine, Department of Medicine, National Taiwan University Hospital, Taipei, Taiwan








(PFGE)* Corresponding author. Division of
Section II, Taipei 11217, Taiwan.
E-mail address: cpfung@vghtpe.go
1684-1182/$36 Copyright ª 2011, Taiw
doi:10.1016/j.jmii.2011.09.004Background/Purpose: The prevalence of ampicillin-resistant Moraxella catarrhalis has been
higher in Taiwan than in other countries, with reports of 97.7% in the 1990s. The aims of this
study were to assess resistance trends for M. catarrhalis, which causes respiratory tract infec-
tions, against several classes of oral antibiotics and to compare the minimum inhibitory concen-
tration (MIC) of antimicrobial agents against M. catarrhalis isolates between 1993e1994 and
2001e2004.
Methods: Clinical isolates of M. catarrhalis (n Z 314) were collected from 11 large medical
centers in Taiwan between 2001 and 2004. b-Lactamase production tests were performed.
The MICs for 13 different oral antibiotics were calculated using the agar dilution method.
Pulsed-field gel electrophoresis (PFGE) was performed for 18 randomly selected high-level ampi-
cillin-resistant (BRO-1 b-lactamase-positive, MIC  32 mg/mL) isolates to investigate their
genetic relatedness.
Results: The overall rate of b-lactamase-producing isolates was 97.8% (307/314). All isolates
were susceptible to amoxicillin þ clavulanate, chloramphenicol, cefixime, ciprofloxacin, eryth-
romycin, levofloxacin, moxifloxacin, and roxithromycin. The rate of resistance to cefaclor and
cefuroxime was 8.3% and 1.3%, respectively, while no resistance was found in 1993e1994. Resis-
tance to trimethoprimesulfamethoxazole (SXT) and tetracycline was 18.5% and 19.8%, respec-
tively. Comparison of 1993e1994 and 2001e2004 isolates revealed that the zone diameter for
amoxicillin þ clavulanate disks decreased from 43 mm in 1993e1994 to 32 mm in 2001e2004
(p < 0.001). However, MIC50 (0.25 mg/mL in both 1993e1994 and 2001e2004) and MIC90
(0.5 mg/mL in both 1993e1994 and 2001e2004) for amoxicillin þ clavulanate did not differInfectious Diseases, Department of Medicine, Taipei Veterans General Hospital, 201 Shih-Pai Road,
v.tw (C.-P. Fung).
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M. catarrhalis in Taiwan 135between the study periods. The PFGE typing results demonstrate that at least two closely
related BRO-1 clones are spreading in Taiwan.
Conclusion: The rates of resistance to cefaclor, cefuroxime, tetracycline and SXT are now
increasing in Taiwan. Molecular typing showed that at least two closely related BRO-1 clones
are circulating. Although amoxicillin þ clavulanate remains the antimicrobial therapy of choice
for M. catarrhalis infections, continued surveillance of antimicrobial susceptibility and applica-
tion of control measures against further transmission are required to inhibit the emergence of
the resistant strains.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Moraxella catarrhalis (formerly Branhamella catarrhalis),
a Gram-negative aerobic diplococcus, has been recognized
as an increasingly important pathogen in respiratory
infections including otitis media, sinusitis, acute bronchitis,
and pneumonia.1,2 It resides exclusively in humans and
colonizes the nasopharynx and occasionally the conjunctiva
and genital tract.3 Colonization of the respiratory tract is
believed to be a precursor of infection, although the
mechanism is not well understood.4 A high percentage (up
to 75%) of colonization was found in infants and decreased
with age.3 The prevalence of colonization in healthy adults
is low (1e3%).5
M. catarrhalis isolates frequently harbor a b-lactamase
enzyme designated BRO (from Branhamella and Moraxella).
Twodistinct BRO-typeb-lactamaseenzymes,BRO-1andBRO-
2, have been found since 1976.6 BRO-positive isolates have
increased rapidly in recent years, and account for more than
80e90% of isolates in Europe and North America7,8 and nearly
98% in Taiwan.9 Although a third BRO enzyme (BRO-3) was
postulated by Christensen et al,10 BRO-3 is now considered to
be a membrane-bound precursor rather than a distinct
enzyme.11 BRO-1 and BRO-2 can be detected by polymerase
chain reaction (PCR) methods using specific primers.12 Our
previous investigation revealed that BRO-1 is the most
common enzyme among b-lactamase-positive isolates (238/
270 isolates, 88%), with only 12% (32/270) of b-lactamase-
producing isolates containing BRO-2.13 Both enzymes are
encoded by chromosomal genes and are phenotypically
identical and membrane-associated. The proteins differ by
only a single amino acid.14 Fung et al showed significant
differences between the geometric mean minimum inhi-
bitory concentration (MIC) of ampicillin for BRO-1- and
BRO-2-producing strains, and smaller differences for
amoxicillin þ clavulanate, loracarbef, cefixime, and cefe-
tamet.15 The difference is attributed to the production of
more enzymes as a consequence of the higher transcriptional
activity of the BRO-1 gene.4,6
The continuing increase in the antibiotic resistance of
respiratory pathogens remains a global problem. Surveil-
lance to monitor shifting trends in resistance is vital and
ultimately influences the selection of antimicrobial agents
available for use against a particular organism.16 Jaecklin
et al emphasized the importance of ongoing antimicrobial
susceptibility surveillance studies at a regional level.17
In this study, we collected 314 M. catarrhalis isolates
from 11 medical centers in Taiwan in 2001e2004 to assessresistance trends for this organism against 13 different oral
antibiotics used to treat respiratory tract infections. The
rapid increase in b-lactamase-producing strains of
M. catarrhalis is a global problem. The ultimate aim of the
study was to obtain a clearer understanding of BRO distri-
butions to gain an insight into clonal spreading in Taiwan.
Therefore, we compared MIC values to those of isolates
obtained in 1993e1994 and determined the genetic relat-




A total of 314 clinical isolates of M. catarrhalis were
consecutively collected from 11 geographically scattered
laboratories in Taiwan in 2001e2004. One isolate was
accepted for each episode of infection. The isolates were
sent to Taipei Veterans General Hospital for further iden-
tification and antimicrobial susceptibility testing. Organ-
isms were immediately subcultured onto chocolate agar
plates to check viability and purity. Identification was
confirmed by Gram stain, colony morphology, hydrolysis of
tributyrin, and positive oxidase and DNase tests.15 b-Lac-
tamase production was confirmed by a nitrocefin test.15
Antimicrobial susceptibility testing
To assess the trends of ampicillin resistance of M. catar-
rhalis, isolates were inoculated into 1 mL of braineheart
infusion (BHI) broth with 5% Fildes’ extract supplement and
incubated for 5 h at 37C. Each suspension was diluted
1:100 in peptone water and swabbed onto Muller-Hinton
(MHA) agar supplemented with 0.25% lysed horse blood.
Disks of 6 mm in diameter containing ampicillin (2 mg) or
amoxicillin þ clavulanate (2 mg þ 1 mg) were applied. All
plates were incubated in 5% CO2 and 95% air at 37
C for
18 h. Zone diameters were measured and recorded to the
nearest whole millimeter.
MIC values for the 13 antimicrobial agents were deter-
mined using an agar dilution technique with horse-blood-
supplemented MHA agar. A Denley multipoint inoculator
(Denley Instruments, Billingshurst, UK) was used to deliver
0.003 mL of 1:100 dilutions of each organism prepared as
for disk testing (104 colony-forming units/spot) to the agar
surface. All plates were incubated in 5% CO2 and 95% air at
Figure 1. Comparison of zone diameters (mm) for ampicillin
and amoxicillin þ clavulanate between 1993e1994 (n Z 124)
and 2001e2004 (n Z 314).
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of an antimicrobial agent that inhibited visible growth.
MIC50 and MIC90 were defined as the minimal concentration
that inhibited 50% and 90% of bacterial growth, respec-
tively. The interpretation of cut-off point for resistance was
based on Clinical Laboratory Standards Institute (CLSI)
recommendations for Haemophilus spp.18 When CLSI
breakpoints were not available, The British Society for
Antimicrobial Chemotherapy (BSAC) breakpoints for eryth-
romycin, ciprofloxacin, levofloxacin, and moxifloxacin and
PK/PD breakpoints for cefixime were used.19 For roxi-
thromycin, we used the resistance criterion (MIC  32 mg/
mL) established by Abdel-Rahman et al.20
Staphylococcus aureus ATCC 29213, Escherichia coli
35218, M. catarrhalis ATCC25238 (b-lactamase-negative)
and M. catarrhalis Ravasio (BRO-1) were used as control
strains. Media, supplements and disks were BD-Difco prod-
ucts purchased from Becton Dickenson (Franklin Lakes, NJ,
USA). Standards were obtained from the following manu-
facturers: ampicillin, chloramphenicol, erythromycin, and
tetracycline from Sigma-Aldrich (St. Louis, MO, USA);
amoxicillin þ clavulanate from GlaxoSmithKline (London,
UK); cefaclor and cefuroxime from Eli Lilly (Indianapolis,
IN, USA); cefixime from Astellas Pharmaceutical (Tokyo,
Japan); levofloxacin from Daiichi Sankyo Company (Tokyo,
Japan); moxifloxacin from Bayer AG (Leverkusen,
Germany); roxithromycin from Hoffmann Le Roche (Basel,
Switzerland) and trimethroprimesulfamethoxazole (SXT)
from Shionogi (Osaka, Japan).
Pulsed field gel electrophoresis
We randomly selected 18 high-level ampicillin-resistant
(MIC  32 mg/mL) M. catarrhalis isolates from different
regions of Taiwan (isolates 1e6 from the northern region,
7e12 from the central region, and 13e18 from the southern
region). Itwas confirmed that these 18 isolateswereBRO-1b-
lactamase-producing strains by isoelectric focusing (IEF).13
The selected isolates were inoculated into supplemented
tryptic soy broth (TSB) and incubatedwith shaking for 18 h at
37C. For restrictionendonuclease digestion, anagaroseplug
containing DNAwas placed into restriction buffer containing
12 U of SpeI (New England Biolabs, Beverly, MA, USA) and
incubated overnight at 37C. Lambda concatamers (Lambda
Ladder PFG marker; New England Biolabs) were used as
molecular weight standards. Electrophoresis was performed
on a contour-clamped homogeneous gel electrophoresis
device (CHEF mapper XA system; Bio-Rad, Hercules, CA,
USA). After staining with ethidium bromide, the gel was
photographed with UV transillumination, and restriction
fragment length polymorphism (RFLP) patterns were deter-
mined by visual inspection of the gels. The band patterns
were compared as previously described by Tenover et al.21 A
dendrogram was generated with GelCompar II statistical
software (Applied Maths NV, St-Martens-Latem, Belgium)
using the Dice coefficient and unweighted paired-group
methods for the arithmetic average algorithm.
Statistical analysis
Statistical analysis was performed using SPSS statistical
software Version 17.0 (SPSS, Chicago, IL, USA). Data forzone diameter, MIC and antibiotic resistance rates between
1993e1994 and 2001e2004 were compared using the Man-
teleHaenszel test, the ManneWhitney U test, and Fisher’s
exact test, respectively. A p value <0.05 was considered as
statistically significant.
Results
A total of 314 isolates from 11 medical centers in different
regions of Taiwan were collected in 2001e2004. Of these,
124 isolates (39.4%) were from northern Taiwan, 98 isolates
(31.2%) were from central Taiwan, 77 isolates (24.5%) were
from southern Taiwan, and 15 isolates (4.8%) were from
eastern Taiwan. The age of patients from whom the isolates
were obtained ranged from 1 to 96 years (mean 38.4 years).
The ratio of males to females was 1.57:1. Among the 314
isolates, 176 (57%) were from sputum, 58 (18.5%) from nasal
or sinus specimens, 12 from wound, nine from throat, three
from blood, three from ear, two from eye and one from
endometrium samples.
All b-lactamase-producing M. catarrhalis isolates were
ampicillin-resistant. The zonal diameter for M. catarrhalis
was 6e28 mm for ampicillin and 25e50 mm for
amoxicillin þ clavulanate. Only seven isolates were suscep-
tible to ampicillin and the overall percentage of b-lacta-
mase-producing isolateswas 97.8%. Themean zone diameter
was 32 mm for amoxicillin þ clavulanate, which was signifi-
cantly different from the 15 mm for ampicillin. Comparison
of data for 1993e199413 and 2001e2004 (Fig. 1) revealed that
the mean zone diameter for amoxicillin þ clavulanate
decreased from 43mm in 1993e1994 to 32 mm in 2001e2004
(p < 0.001). However, MIC50 (0.25 mg/mL in both 1993e1994
and 2001e2004) andMIC90 (0.5 mg/mL in both 1993e1994 and
2001e2004) for amoxicillin þ clavulanate did not change
between the study periods.
All isolates were susceptible to amoxicillinþ clavulanate,
chloramphenicol, cefexime, ciprofloxacin, erythromycin,
Figure 2. Rate of resistance to ampicillin, cefaclor,
trimethoprim þ sulfamethoxazole (SXT) and tetracycline for M.
catarrhalis isolates from northern, central and southern
Taiwan (2001e2004). SXT, p < 0.001 for central versus north
and p < 0.01 for south versus central. Tetracycline, p < 0.005
for central versus north and p < 0.05 for south versus central.
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26 isolates (8.3%)were resistant to cefaclor, four (1.3%)were
resistant to cefuroxime, 58 (18.5%)were resistant to SXT, and
62 (19.5%) were resistant to tetracycline (Table 1). Among
the isolates from different regions, the rate of resistance to
SXT was 8.1% in the northern region, 32.7% in the central
region, and 14.3% in the southern region (p< 0.001 central vs
north, p < 0.01 south vs central). The rate of resistance to
tetracycline was 15.3%, 32.7%, and 16.9% in the northern,
central, and southern regions, respectively (p < 0.005
central vs north, p < 0.05 south vs central; Fig. 2). To
investigate the possibility of BRO-1 clonal spreading, a total
of 18 high-level ampicillin-resistant isolates (BRO-1-positive,
MIC  32 mg/mL) randomly selected from different
geographical regions were analyzed by PFGE. The resulting
dendrogram shows diverse group clusters in SpeI-digested
PFGE patterns of isolates (Fig. 3). Isolates 2 (from the
northern region) and 8 (from central region) had closely
related banding patterns, and isolates 11 (from the central
region) and 18 (from the southern region) had closely related
PFGE profiles. Genomic typing demonstrated that at least
two closely related M. catarrhalis clones had been trans-
mitted in three regions of Taiwan, which indicates that high-
level ampicillin-resistant strains are spreading in the
country.Disscussion
M. catarrhalis, previously considered a harmless
commensal organism, has gained recognition as a pathogen
over the past three decades and has shown increased
prevalence of b-lactamase production. Before 1976, there
were no reports of b-lactamase-producing strains of
M. catarrhalis.6 However, a study using isolates obtained inTable 1 Comparative in vitro activity of 13 antimicrobial agen
Antimicrobial agent MIC in 2001e2
Range M
Ampicillin 0.008e64 8










Trimethoprim þ sulfamethoxazole 0.12e8 0
Tetracycline 0.25e128 0
a CLSI breakpoints for resistance: ampicillin 4 mg/mL, amoxicillin þ
cefaclor 32 mg/mL, cefuroxime 16 mg/mL, tetracycline 8 mg/mL,
breakpoints for resistance: erythromycin 16 mg/mL, ciprofloxacin 
breakpoint for resistance: cefixime 2 mg/mL. Breakpoint for resista
b TMP 100% resistant, SMX 9.6% resistant.
*Significant increase in resistance compared with 1994 (p < 0.05).
MIC Z minimum inhibitory concentration; N Z test not performed inthe late 1980s from the UK revealed that 90% were b-lac-
tamase producers.7,22 In Taiwan, the prevalence of
ampicillin-resistant M. catarrhalis is high, with a report of
97.7% in 1994.9 The present finding (97.8% b-lactamase
producers) is compatible with previous studies.9,23 The
dramatic increase in the frequency of b-lactamase-
producing M. catarrhalis strains could be regarded as the
fastest dissemination of any known b-lactamase within
a bacterial species.6,23
The well-known mechanism of aminopenicillin resis-
tance in M. catarrhalis involves the expression of one of
two chromosomally encoded BRO b-lactamases, detectablets against 314 M. catarrhalis isolates
004 (mg/mL) Resistance (%)a
IC50 MIC90 2001e2004 1993e1994
32 97.8 97.7
.25 0.5 0 0
.5 1 0 0
16 8.3* 0
4 1.3 0
.06 0.5 0 0
.25 0.5 0 0
.25 1 0 0
.06 1 0 N
.12 0.25 0 N
.5 2 0 0
.5 8 18.5 100/9.6b
.5 64 19.8 14
clavulanate (2:1 ratio) 8/4 mg/mL, chloramphenicol 8 mg/mL,
trimethoprimesulfamethoxazole(1:19 ratio) 4/76 mg/mL. BSAC
1 mg/mL, levofloxacin 2 mg/mL, moxifloxacin 1 mg/mL. PK/PD
nce: roxithromycin 32 mg/mL.18
1993e1994.
Figure 3. Pulsed-field gel electrophoresis profiles for 18
high-level ampicillin-resistant M. catarrhalis isolates. (A) DNA
fragments were digested using SpeI restriction endonuclease.
Lane MZ molecular weight marker; lanes 1e6Z isolates from
northern Taiwan; lanes 7e12 Z isolates from central Taiwan;
lanes 13e18Z isolates from southern Taiwan. (B) Dendrogram
showing clustering of SpeI-digested PFGE patterns for isolates.
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a significant increase in MIC for ampicillin and amoxicillin in
M35 porin-deficient mutants,24 which suggests that this
porin affects outer membrane permeability for amino-
penicillins in a clinically relevant manner.
The mean zone diameter for amoxicillin þ clavulanate
decreased from 43 mm in 1993e1994 to 32 mm in
2001e2004. However, the MIC90 value in 2001e2004
(0.5 mg/mL) was the same as that in 1993e1994. The reason
for the change in zone diameter is not clear, but it is
possible that the proportion of BRO-1- and BRO-2-producing
isolates changed. We did not perform analytical IEF or PCR
for BRO-1 and BRO-2 detection for all ampicillin-resistant
isolates, so we could not calculate the percentage of
BRO-1 and BRO-2 isolates. According to our previous study,
the geometric mean amoxicillin þ clavulanate MIC was
threefold higher for BRO-1 producers than for BRO-2
producers.13 Therefore, if the proportion of BRO-1isolates were increasing, the zone diameter for
amoxicillin þ clavulanate would decrease.
In present study, activity based on the MIC90 of cepha-
losporin was ranked in the order cefixime (0.5 mg/
ml) > cefuroxime (4 mg/ml) > cefaclor (16 mg/ml). The rate
of resistance to cefaclor and cefuroxime was 8.3% and 1.3%,
respectively, while no resistance was found in 1993e1994.
Interestingly, comparison of data between 1993e1994 and
2001e2004 revealed an increase in MIC90 for cefaclor (1 mg/
mL in 1993e1994 vs 16 mg/mL in 2001e2004, p < 0.01) and
cefuroxime (2 mg/mL in 1993e1994 vs 4 mg/mL in
2001e2004, p < 0.01), which is consistent with the signifi-
cant increase in resistance to cefaclor (8.28% in 2004, 0% in
1993e1994, p < 0.05). Kadry et al suggested that BRO b-
lactamases might give some protection against many of the
newer cephems.25 An investigation of trends in antibiotic
resistance of 375 M. catarrhalis isolates in a single hospital
over a 10-year period (1984e1994) revealed the increased
MIC was not due to an increase in the frequency of b-lac-
tamase-producing strains, but rather occurred mainly
within the group of b-lactamase-positive strains.26 The
same phenomenon was also found for tetracycline
(MIC9016 mg/mL in 1993e1994 vs 64 mg/mL in 2001e2004,
p < 0.01), which suggests that continual monitoring of M.
catarrhalis resistance to these antibiotics is necessary. The
rate of resistance to SXT was 18.5%, which could not be
compared with results for trimethoprim (100%) and sulfa-
methoxazole (9.6%) in 1993e1994 owing to the combination
(1:19 ratio) used in this study. However, The SENTRY
surveillance program in 1997e1999 found a rate of resis-
tance to SXT of only 0.1%e2.6%27 and Karpanoja et al found
a rate of 3.2e14.5%.28 Compared with the data in recent
studies, the rate of resistance to SXT is higher in
Taiwan.23,27,28 Our isolates were geographically dispersed
and the rate of resistance to SXT was higher in the central
region (32.7%) than in northern (8.1%) and southern (14.3%)
regions of Taiwan. The reason for this increase in SXT
resistance is not clear. Many studies have provided
evidence of a connection between increased consumption
and increased resistance to certain antimicrobial
agents.29,30 However, a study that collected 14,138 M.
catarrhalis isolates between 1998 and 2004 found no
statistically significant association between regional SXT
use and resistance in M. catarrhalis.28
In this study, PFGE analysis was carried out for high-level
ampicillin-resistant (MIC  32 mg/mL) isolates confirmed as
BRO-1-producing strains from different regions of Taiwan.
Although the selected number was small (18/307, 5.9%), we
found two closely related BRO-1 clones in northern, central
and southern regions, which indicates that these clones are
spreading in Taiwan. According to a report from Japan, M.
catarrhalis can be transmitted from patient to patient.31
Preventive measures such as hand-washing and mask and
glove protection for healthcare workers should be adopted
to control hospital outbreaks.
In conclusion, the rates of resistance to cefaclor, cefur-
oxime, tetracycline and SXT are now increasing in Taiwan,
Molecular typing showed that at least two closely related
BRO-1 clones are circulating. Although amoxicillin þ
clavulanate remains the antimicrobial therapy of choice for
M. catarrhalis infections, continued surveillance of antimi-
crobial susceptibility and application of control measures
M. catarrhalis in Taiwan 139against further transmission are required to decrease the
emergence of the resistant strains.
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